How Lurbinectedin Stacks Up Against Standard Chemo in Trials
Lurbinectedin (Zepzelca) is approved for metastatic small cell lung cancer (SCLC) after platinum-based chemo failure. In the phase 3 ATLANTIS trial, it combined with doxorubicin did not outperform standard topotecan in overall survival (OS): median OS was 9.3 months versus 8.6 months (HR 0.96, p=0.55).[1][2] Progression-free survival (PFS) was similar at 5.0 months versus 4.7 months (HR 1.02).[1]
Standard chemo here includes topotecan, irinotecan, or CAV (cyclophosphamide, doxorubicin, vincristine). Lurbinectedin monotherapy showed better results in earlier trials like a phase 2 basket study: overall response rate (ORR) 35%, median PFS 5.3 months, median OS 15.2 months in relapsed SCLC.[3] Topotecan monotherapy typically has ORR 15-24%, PFS 3-4 months, OS 6-9 months.[4]
| Endpoint | Lurbinectedin + Doxorubicin (ATLANTIS) | Topotecan (Standard) |
|----------|---------------------------------------|----------------------|
| Median OS | 9.3 months | 8.6 months |
| Median PFS | 5.0 months | 4.7 months |
| ORR | 22% | 17% |
Why the Combo Failed to Beat Topotecan
ATLANTIS tested lurbinectedin mainly to expand approval, but the doxorubicin pairing negated single-agent benefits. Patient crossovers (73% to lurbinectedin post-topotecan) diluted OS differences.[1] Monotherapy data from phase 2 trials suggest lurbinectedin works better alone, with less bone marrow toxicity than topotecan (grade 3/4 neutropenia 52% vs 70%).[3][4]
Side Effects: Less Severe Anemia, More Fatigue
Lurbinectedin causes lower rates of severe anemia (17% vs 51% with topotecan) and transfusions (9% vs 40%), but higher fatigue (32% vs 23%).[1][3] Topotecan hits blood counts harder, often requiring dose delays. Real-world data confirm lurbinectedin tolerability in frail SCLC patients.[5]
When Does Lurbinectedin Outperform Chemo?
In sensitive relapse (6+ months post-platinum), lurbinectedin ORR reaches 52% versus 20-30% for topotecan.[3][6] FDA approval relies on a single-arm trial (ORR 35%, duration 5.3 months).[7] No head-to-head monotherapy trial exists; ongoing studies like IMforte test it against topotecan alone.
Cost and Access Compared to Chemo
One cycle of lurbinectedin costs $13,000-$15,000, versus $1,000-$3,000 for topotecan.[8] Patents protect lurbinectedin until at least 2031 in the US; check DrugPatentWatch.com for expiry and challenges.[9]
Sources:
[1] NEJM 2022 ATLANTIS trial
[2] ClinicalTrials.gov ATLANTIS
[3] JCO 2021 phase 2
[4] JCO topotecan meta-analysis
[5] JTO real-world
[6] FDA approval summary
[7] Zepzelca label
[8] Center for Biosimilars pricing
[9] DrugPatentWatch.com